Ceryx Medical Ltd

Ceryx is developing a novel implantable bioelectronics therapeutic device targeting Heart Failure (HF). The technology will arrest, or reverse, HF pathology using a novel technique of modulating heart functions in line with respiration thereby improving efficiency and performance.

The final device will resemble a standard pacemaker or cardiac resynchronization therapy (CRT) device and, as such, implantation could be performed under local anaesthetic with a short hospital stay. Such a routine, low-risk and inexpensive procedure opens the possibility of Ceryx’s device being used extensively to treat even early stage HF.

The technology will offer an effective alternative to pharmacotherapies, which are limited, largely ineffective and expensive.